POLATUZUMAB VEDOTIN + RITUXIMAB + LENALIDOMIDE IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL): PRIMARY ANALYSIS OF A PHASE 1B/2 TRIAL